Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Inactivated SARS-CoV-2 vaccine (Osman Erganis)
- Development stage
- Unknown
- Lead developer
- Selçuk University
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
This is an adjuvanted, inactivated whole-virus vaccine candidate developed against SARS-CoV-2 by a research team led by Professor Osman Erganis at Selcuk University in Turkey. The vaccine utilizes a traditional inactivated virus platform, where the SARS-CoV-2 virus is grown in culture and then chemically inactivated to lose its pathogenicity while retaining its immunogenic properties. It is formulated with an adjuvant to enhance the immune response. In clinical trials, it has been administered via subcutaneous injection, which distinguishes it from many other COVID-19 vaccines that are typically administered intramuscularly. The primary goal of the vaccine is to induce protective immunity against COVID-19 in healthy adults by presenting the entire killed virus to the immune system, thereby triggering a broad response against multiple viral proteins.
- Other names
- SARS-CoV-2 vaccine-Osman ERGANISSARS-CoV2 vaccine-Osman ERGANISSARS-CoV 2 vaccine-Osman ERGANISSelcuk University COVID-19 vaccineSelcuk University inactivated SARS-CoV-2 vaccine
02
Targets
E (Tick-borne encephalitis virus envelope protein)M protein (SARS-CoV-2 membrane protein)N (Nucleocapsid protein)SARS-CoV-2 spike
Beyond the preview
Go deeper on Inactivated SARS-CoV-2 vaccine (Osman Erganis).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inactivated SARS-CoV-2 vaccine (Osman Erganis).